The physiological role of endoglin in the cardiovascular system

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 4, 2010, Pages

  López Novoa, José M ^a   Bernabeu, Carmelo ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Angiogenesis; Development; Nitric oxide; Vascular malformations

Indexed keywords

ENDOGLIN; ENDOGLIN RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE MUTATION; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RENDU OSLER WEBER DISEASE; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VASCULAR REMODELING;

ANIMALS; ANTIGENS, CD; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTORS;

EID: 77958046834     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01251.2009     Document Type: Review

References (179)

1. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 43: 97-110, 2006. (Pubitemid 43262964)
2. Adam PJ, Clesham GJ, Weissberg PL. Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun 247: 33-37, 1998. (Pubitemid 28412520)
3. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-478, 2007.
4. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M. Expression and structural features of endoglin (CD105), a transforming growth factor β1 and β3 binding protein, in human melanoma. Br J Cancer 74: 1586-1591, 1996. (Pubitemid 26386086)
5. Alvarez-Muñoz P, Mauer M, Kim Y, Rich SS, Miller ME, Russell GB, López-Novoa JM, Caramori ML. Cellular basis of diabetic nephropathy: V. Endoglin expression levels and diabetic nephropathy risk in patients with Type 1 diabetes. J Diabetes Complications 24: 242-249, 2010.
6. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, Charlton R, Parums DV, Jowett T, Marchuk DA, Burn J, Diamond AG. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217: 42-53, 2000. (Pubitemid 30046798)
7. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997. (Pubitemid 27087709)
8. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594, 1999.
9. Barresi V, Grosso M, Vitarelli E, Triolo O, Barresi G. Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study. Reprod Sci 15: 1018-1026, 2008.
10. Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, Tuncali T. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 140: 2155-2162, 2006. (Pubitemid 44522429)
11. Belik J, Jerkic M, McIntyre BA, Pan J, Leen J, Yu LX, Henkelman RM, Toporsian M, Letarte M. Age-dependent endothelial nitric oxide synthase uncoupling in pulmonary arteries of endoglin heterozygous mice. Am J Physiol Lung Cell Mol Physiol 297: L1170-L1178, 2009.
12. Bellon T, Corbi A, Lastres P, Cales C, Cebrián M, Vera S, Cheifetz S, Massague J, Letarte M, Bernabeu C. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993. (Pubitemid 23265903)
13. Bernabeu C, López-Novoa JM, Quintanilla M. An emerging role of TGF-β co-receptors in cancer. Biochim Biophys Acta 1792: 954-973, 2009.
14. Blanco FJ, Grande MT, Langa C, Oujo B, Velasco S, Rodriguez- Barbero A, Perez-Gomez E, Quintanilla M, López-Novoa JM, Bernabeu C. S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 103: 1383-1392, 2008.
15. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204: 574-584, 2005. (Pubitemid 40934653)
16. Blann AD, Wang JM, Wilson PB, Kumar S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 120: 221-226, 1996. (Pubitemid 26053317)
17. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 26: 1712-1720, 2006. (Pubitemid 44305323)
18. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 18: 2701-2710, 1998. (Pubitemid 28386569)
19. Bossler AD, Richards J, George C, Godmilow L, Ganguly A. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 27: 667-675, 2006.
20. Botella LM, Sánchez-Elsner T, Rius C, Corbí A, Bernabéu C. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 276: 34486-34494, 2001.
21. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100: 4001-4010, 2002. (Pubitemid 35396866)
22. Botella LM, Sanz-Rodriguez F, Sanchez-Elsner T, Langa C, Ramirez JR, Vary C, Roughley PJ, Bernabeu C. Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol 22: 561-572, 2004. (Pubitemid 38283780)
23. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104: 1343-1351, 1999.
24. Braverman IM, Keh A, Jacobson BS. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 95: 422-427, 1990. (Pubitemid 20331987)
25. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995. (Pubitemid 26030991)
26. Calabro L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Sigalotti L, Altomonte M, Musolino C, Maio M. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 194: 171-175, 2003. (Pubitemid 36043631)
27. Capettini LS, Cortes SF, Gomes MA, Silva GA, Pesquero JL, Lopes MJ, Teixeira MM, Lemos VS. Neuronal nitric oxide synthase-derived hydrogen peroxide is a major endothelium-dependent relaxing factor. Am J Physiol Heart Circ Physiol 295: H2503-H2511, 2008.
28. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 6: 315-326, 2009.
29. Carvalho RL, Jonker L, Goumans MJ, Larsson J, Bouwman P, Karlsson S, Dijke PT, Arthur HM, Mummery CL. Defective paracrine signalling by TGF-β in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 131: 6237-6247, 2004. (Pubitemid 40123935)
30. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
31. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 95: 1167-1173, 2004. (Pubitemid 39648207)
32. Chen Y, Hao Q, Kim H, Su H, Letarte M, Karumanchi SA, Lawton MT, Barbaro NM, Yang GY, Young WL. Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann Neurol 66: 19-27, 2009.
33. Cho SK, Bourdeau A, Letarte M, Zúñiga-Pflücker JC. Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood 98: 3635-3642, 2001.
34. Clemente M, Núñez O, Lorente R, Rincón D, Matilla A, Salcedo M, Catalina MV, Ripoll C, Iacono OL, Bañares R, Clemente G, García- Monzón C. Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat 13: 625-632, 2006. (Pubitemid 44232547)
35. Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42: 577-582, 2005. (Pubitemid 40993833)
36. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. Endoglin, a TGF-β receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153: 323-335, 2000. (Pubitemid 32120331)
37. Cousin M, Custaud MA, Baron-Menguy C, Toutain B, Dumont O, Guihot AL, Vessières E, Subra JF, Henrion D, Loufrani L. Role of angiotensin II in the remodeling induced by a chronic increase in flow in rat mesenteric resistance arteries. Hypertension 55: 109-115, 2010.
38. Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A, Martín-Moreiras J, Pericacho M, Sánchez PL, Ramirez V, Sánchez-Ledesma M, Martín-Herrero F, Jiménez-Candil J, Maree AO, Sánchez- Rodríguez A, Martín-Luengo C, López-Novoa JM. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med 12: 955-961, 2008. (Pubitemid 351718073)
39. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115: 1789-1797, 2007. (Pubitemid 46648616)
40. David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 20: 203-212, 2009.
41. David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis- Girod S, Plauchu H, Feige JJ, Bailly S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 102: 914-922, 2008. (Pubitemid 351591550)
42. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor- like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961, 2007.
43. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, Dechend R, Luft FC. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 15: 2440-2448, 2004.
44. Dharmapatni AA, Smith MD, Ahern MJ, Simpson A, Li C, Kumar S, Roberts-Thomson PJ. The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 19: 275-282, 2001. (Pubitemid 34436221)
45. Dietmann A, Helbok R, Lackner P, Fischer M, Reindl M, Lell B, Issifou S, Kremsner PG, Schmutzhard E. Endoglin in African children with Plasmodium falciparum malaria: a novel player in severe malaria pathogenesis? J Infect Dis 200: 1842-1848, 2009.
46. Diez-Marques L, Ortega-Velazquez R, Langa C, Rodriguez-Barbero A, López-Novoa JM, Lamas S, Bernabeu C. Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta 1587: 36-44, 2002. (Pubitemid 34493832)
47. Docherty NG, López-Novoa JM, Arevalo M, Düwel A, Rodriguez- Peña A, Pérez-Barriocanal F, Bernabeu C, Eleno N. Endoglin regulates renal ischaemia-reperfusion injury. Nephrol Dial Transplant 21: 2106-2119, 2006. (Pubitemid 44295035)
48. 2 production in mouse cerebral arteries. Cardiovasc Res 73: 73-81, 2007.
49. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17: 984-992, 2003. (Pubitemid 36676386)
50. Düwel A, Eleno N, Jerkic M, Arevalo M, Bolaños JP, Bernabeu C, López-Novoa JM. Reduced tumor growth and angiogenesis in endoglinhaploinsufficient mice. Tumour Biol 28: 1-8, 2007. (Pubitemid 46012460)
51. Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F, Pericacho M, Rodriguez-Barbero A, Eleno N, López-Novoa JM, Düwell A, Vega MA, Bernabeu C, Botella LM. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum Mol Genet 16: 1515-1533, 2007. (Pubitemid 47050666)
52. Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat 27: 295, 2006.
53. Fernández-Ruiz E, St-Jacques S, Bellón T, Letarte M, Bernabéu C. Assignment of the human endoglin gene (END) to 9q34→qter. Cyto-genet Cell Genet 64: 204-207, 1993. (Pubitemid 23309620)
54. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immunol 82: 106-111, 2009.
55. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6: 2037-2043, 2000. (Pubitemid 30305103)
56. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumors. Cardiovasc Res 86: 12-19, 2010.
57. Fontalba A, Fernandez-L A, García-Alegria E, Albiñana V, Garrido- Martin EM, Blanco FJ, Zarrabeitia R, Perez-Molino A, Bernabeu- Herrero ME, Ojeda ML, Fernandez-Luna JL, Bernabeu C, Botella LM. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia. BMC Med Genet 9: 75, 2008.
58. Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K, Kodera M, Takehara K, Sato S. A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 213: 88-92, 2006. (Pubitemid 44215191)
59. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363: 852-859, 2004. (Pubitemid 38368834)
60. Ge AZ, Butcher EC. Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand. Gene 138: 201-206, 1994.
61. Gilbert JS, Gilbert SA, Arany M, Granger JP. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 53: 399-403, 2009.
62. Gordon KJ, Blobe GC. Role of transforming growth factor-beta super-family signaling pathways in human disease. Biochim Biophys Acta 1782: 197-228, 2008.
63. Gougos A, Letarte M. Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. J Immunol 141: 1934-1940, 1988.
64. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
65. Gougos A, St Jacques S, Greaves A, O'Connell PJ, d'Apice AJ, Bühring HJ, Bernabeu C, van Mourik JA, Letarte M. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4: 83-92, 1992.
66. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 19: 116-127, 2009.
67. Goumans MJ, Mummery C. Functional analysis of the TGF-β receptor/ Smad pathway through gene ablation in mice. Int J Dev Biol 44: 253-265, 2000. (Pubitemid 30368069)
68. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753, 2002. (Pubitemid 34614630)
69. Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 17: 860-871, 2009.
70. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175-189, 2006. (Pubitemid 43069318)
71. Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S. CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res 24: 1337-1345, 2004. (Pubitemid 38954647)
72. Guerrero-Esteo M, Lastres P, Letamendía A, Pérez-Alvarez MJ, Langa C, López LA, Fabra A, García-Pardo A, Vera S, Letarte M, Bernabéu C. Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 78: 614-623, 1999. (Pubitemid 29484119)
73. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 277: 29197-29209, 2002.
74. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 333: 918-924, 1995.
75. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. Matrix metalloproteinase-14 (MT1- MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70: 4141-4150, 2010.
76. Jain RK. Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003.
77. Jerkic M, Rivas-Elena JV, Prieto M, Carrón R, Sanz- Rodríguez F, Pérez-Barriocanal F, Rodríguez-Barbero A, Bernabéu C, López- Novoa JM. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 18: 609-611, 2004.
78. Jerkic M, Rivas-Elena JV, Santibanez JF, Prieto M, Rodríguez- Barbero A, Perez-Barriocanal F, Pericacho M, Arévalo M, Vary CP, Letarte M, Bernabeu C, López-Novoa JM. Endoglin regulates cyclooxygenase- 2 expression and activity. Circ Res 99: 248-256, 2006. (Pubitemid 44174932)
79. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Wang A, Pérez-Barriocanal F, Arévalo M, Bernabéu C, Letarte M, López-Novoa JM. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 69: 845-854, 2006. (Pubitemid 43227983)
80. Jonker L, Arthur HM. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev 110: 193-196, 2002. (Pubitemid 34020640)
81. Jovine L, Darie CC, Litscher ES, Wassarman PM. Zona pellucida domain proteins. Annu Rev Biochem 74: 83-114, 2005.
82. Kimura C, Cheng W, Hisadome K, Wang YP, Koyama T, Karashima Y, Oike M, Ito Y. Superoxide anion impairs contractility in cultured aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 283: H382-H390, 2002. (Pubitemid 34705361)
83. Koleva RI, Conley BA, Romero D, Riley KS, Marto JA, Lux A, Vary CP. Endoglin structure and function: determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J Biol Chem 281: 25110-25123, 2006. (Pubitemid 44401898)
84. Konduri GG, Ou J, Shi Y, Pritchard KA Jr. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 285: H204-H211, 2003. (Pubitemid 36736431)
85. Kumar P, Wang JM, Bernabeu C. CD 105 and angiogenesis. J Pathol 178: 363-366, 1996.
86. Landburg PP, Elsenga H, Schnog JB, Duits AJ; CURAMA Study Group. Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell disease. Acta Haematol 120: 130-133, 2008.
87. Lastres P, Bellon T, Cabañas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22: 393-397, 1992.
88. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, López LA, Langa C, Fabra A, Letarte M, Bernabéu C. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1115, 1996.
89. Lastres P, Martín-Perez J, Langa C, Bernabéu C. Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 301: 765-768, 1994.
90. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi- Wen X, Chen Y, Venstrom K, Dou X, Ponticos M, Black C, Bernabeu C, Jackman JK, Findell PR, Connolly MK. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 46: 1857-1865, 2002. Erratum in Arthritis Rheum 46: 2830, 2002.
91. Lebrin F, Deckers M, Bertolino P, ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 65: 599-608, 2005. (Pubitemid 40138980)
92. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 23: 4018-4028, 2004. (Pubitemid 39472423)
93. Lebrin F, Mummery CL. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 18: 25-32, 2008.
94. Lenato GM, Lastella P, Di Giacomo MC, Resta N, Suppressa P, Pasculli G. DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population. Hum Mutat 27: 213-214, 2006.
95. Lesca G, Burnichon N, Raux G, Tosi M, Pinson S, Marion MJ. Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. Hum Mutat 27: 598, 2006.
96. Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabeu C. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 273: 33011-33019, 1998. (Pubitemid 28557696)
97. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683, 2004. (Pubitemid 38364626)
98. Li C, Guo B, Ding S, Rius C, Langa C, Kumar P, Bernabeu C, Kumar S. TNFα down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGFβ1. Anticancer Res 23: 1189-1196, 2003. (Pubitemid 36754077)
99. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89: 122-126, 2000. (Pubitemid 30185919)
100. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14: 55-64, 2000. (Pubitemid 30051523)
101. Li C, Issa R, Kumar P, Hampson IN, López-Novoa JM, Bernabeu C, Kumar S. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 116: 2677-2685, 2003. (Pubitemid 36857221)
102. Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 152: 249-256, 2000.
103. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537, 1999.
104. Linder S, Aepfelbacher M. Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol 13: 376-385, 2003. (Pubitemid 36776715)
105. Llorca O, Trujillo A, Blanco FJ, Bernabeu C. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J Mol Biol 365: 694-705, 2007. (Pubitemid 44960353)
106. López-Holgado N, Alberca M, Sanchez-Guijo FM, Villaron EM, Rivas JV, López-Novoa JM, Brinon JG, Arevalo MA, Oterino E, Santamaria C, San Miguel1 JF, Del Canizo MC. Prospective comparative analysis of the angiogenic capacity of monocytes and CD133(+) cells in a murine model of hind limb ischemia. Cytotherapy 11: 1041-1051, 2009.
107. López-Novoa JM. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant 22: 712-714, 2007.
108. Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 21: 3052-3054, 2006.
109. Luque Contreras D, Vargas Robles H, Romo E, Rios A, Escalante B. The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 112: 553-563, 2006. (Pubitemid 44486414)
110. Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, O'Brien E. Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 20: 2546-2552, 2000.
111. Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 205: 491-501, 2008. (Pubitemid 351281612)
112. Mahmoud M, Allinson KR, Zhai Z, Oakenfull R, Ghandi P, Adams RH, Fruttiger M, Arthur HM. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106: 1425-1433, 2010.
113. Mahmoud M, Borthwick GM, Hislop AA, Arthur HM. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH. Lab Invest 89: 15-25, 2009.
114. Mancini ML, Terzic A, Conley BA, Oxburgh LH, Nicola T, Vary CP. Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis. Dev Dyn 238: 2479-2493, 2009.
115. Mancini ML, Verdi JM, Conley BA, Nicola T, Spicer DB, Oxburgh LH, Vary CP. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev Biol 308: 520-533, 2007. (Pubitemid 47223119)
116. Massagué J, Gomis RR. The logic of TGFbeta signalling. FEBS Lett 580: 2811-2820, 2006.
117. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5: 371-382, 1999. (Pubitemid 29085191)
118. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351, 1994.
119. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Müller R, Adamkiewicz J. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81: 568-572, 1999. (Pubitemid 29203054)
120. Moreau V, Tatin F, Varon C, Génot E. Actin can reorganize into podosomes in aortic endothelial cells, a process controlled by Cdc42 and RhoA. Mol Cell Biol 23: 6809-6822, 2003. (Pubitemid 37214652)
121. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 23: 1407-1415, 2008. (Pubitemid 351770590)
122. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 277: 44085-44092, 2002. (Pubitemid 36157836)
123. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145: 4838-4845, 2004. (Pubitemid 39551100)
124. Nurkiewicz TR, Boegehold MA. High salt intake reduces endothelium-dependent dilation of mouse arterioles via superoxide anion generated from nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 292: R1550-R1556, 2007.
125. Obreo J, Díez-Marques L, Lamas S, Düwell A, Eleno N, Bernabéu C, Pandiella A, López-Novoa JM, Rodríguez-Barbero A. Endoglin expression regulates basal and TGF-β-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem 14: 301-310, 2004. (Pubitemid 39179199)
126. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631, 2000. (Pubitemid 30159221)
127. Ozaki M, Kawashima S, Yamashita T, Ohashi Y, Rikitake Y, Inoue N, Hirata KI, Hayashi Y, Itoh H, Yokoyama Hypertension M. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 37: 322-327, 2001. (Pubitemid 32199094)
128. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E, Wrana JL, Letarte M. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 280: 27800-27808, 2005. (Pubitemid 41076895)
129. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8: 21-43, 1997.
130. Pérez-Gómez E, Eleno N, López-Novoa JM, Ramirez JR, Velasco B, Letarte M, Bernabéu C, Quintanilla M. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 24: 4450-4461, 2005. (Pubitemid 40961768)
131. Perlingeiro RC. Endoglin is required for hemangioblast and early hematopoietic development. Development 34: 3041-3048, 2007. (Pubitemid 47386915)
132. Post S, Smits AM, van den Broek AJ, Sluijter JP, Hoefer IE, Janssen BJ, Snijder RJ, Mager JJ, Pasterkamp G, Mummery CL, Doevendans PA, Goumans MJ. Impaired recruitment of HHT-1 mononuclear cells to the ischemic heart is due to an altered CXCR4/CD26 balance. Cardiovasc Res 85: 494-502, 2010.
133. Preativatanyou K, Honsawek S, Chongsrisawat V, Vejchapipat P, Theamboonlers A, Poovorawan Y. Correlation of circulating endoglin with clinical outcome in biliary atresia. Eur J Pediatr Surg. In press.
134. Purwosunu Y, Sekizawa A, Yoshimura S, Farina A, Wibowo N, Nakamura M, Shimizu H, Okai T. Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. Reprod Sci 16: 857-864, 2009.
135. Qu R, Silver MM, Letarte M. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during
136. Quintanilla M, Ramirez JR, Pérez-Gómez E, Romero D, Velasco B, Letarte M, López-Novoa JM, Bernabéu C. Expression of the TGF-β coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Oncogene 22: 5976-5985, 2003. (Pubitemid 37179945)
137. Rahman A, Swärd K. The role of caveolin-1 in cardiovascular regulation. Acta Physiol (Oxf) 195: 231-245, 2009.
138. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 25: 763-769, 2004. (Pubitemid 39276941)
139. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308: 1592-1594, 2005.
140. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107: 1164-1169, 2003. (Pubitemid 36297209)
141. Risau W. Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
142. Rius C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CP, Bernabeu C. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 92: 4677-4690, 1998. (Pubitemid 29005870)
143. Rodriguez-Pena A, Eleno N, Duwell A, Arevalo M, Perez-Barriocanal F, Flores O, Docherty N, Bernabeu C, Letarte M, López-Novoa JM. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 40: 713-720, 2002. (Pubitemid 35278609)
144. Romero D, Terzic A, Conley BA, Craft C, Jovanovic B, Bergan R, Vary CP. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 31: 359-366, 2010.
145. Rulo HF, Westphal JR, van de Kerkhof PC, de Waal RM, van Vlijmen IM, Ruiter DJ. Expression of endoglin in psoriatic involved and uninvolved skin. J Dermatol Sci 10: 103-109, 1995.
146. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 277: 43799-43808, 2002. (Pubitemid 36157800)
147. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, López-Novoa JM, Attisano L, Bernabeu C. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 210: 456-468, 2007. (Pubitemid 44956891)
148. Saura M, Zaragoza C, Cao W, Bao C, Rodríguez-Puyol M, Rodríguez-Puyol D, Lowenstein CJ. Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res 91: 806-813, 2002. (Pubitemid 35285078)
149. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Löwik CW, ten Dijke P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120: 964-972, 2007. (Pubitemid 46638511)
150. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor- beta1 and BMP-7 signaling. J Biol Chem 282: 13934-13943, 2007. (Pubitemid 47100463)
151. Seki T, Hong KH, Oh SP. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 86: 116-129, 2006. (Pubitemid 43117592)
152. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-β in suppression of growth of human endothelial cells. Int J Cancer 108: 251-257, 2004. (Pubitemid 37541779)
153. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12: 473-482, 2003. (Pubitemid 36305588)
154. Suvorava T, Lauer N, Kumpf S, Jacob R, Meyer W, Kojda G. Endogenous vascular hydrogen peroxide regulates arteriolar tension in vivo. Circulation 112: 2487-2495, 2005. (Pubitemid 41504499)
155. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE. Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76: 187-194, 1995.
156. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/ severe combined immunodeficiency mouse chimeras by antiendoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61: 7846-7854, 2001. (Pubitemid 33049374)
157. ten Dijke P, Arthur HM. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869, 2007.
158. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89, 2008.
159. Thomas B, Eyries M, Montagne K, Martin S, Agrapart M, Simerman- François R, Letarte M, Soubrier F. Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia. Eur J Clin Invest 37: 580-588, 2007. (Pubitemid 46920194)
160. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96: 684-692, 2005. (Pubitemid 40478336)
161. Toporsian M, Jerkic M, Zhou YQ, Kabir MG, Yu LX, McIntyre BA, Davis A, Wang YJ, Stewart DJ, Belik J, Husain M, Henkelman M, Letarte M. Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 30: 509-517, 2010.
162. Torsney E, Charlton R, Diamond AG, Burn J, Soames JV, Arthur HM. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 107: 1653-1657, 2003. (Pubitemid 36397335)
163. Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51: 464-470, 2002. (Pubitemid 35034452)
164. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, Seon BK. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 122: 2266-2273, 2008. (Pubitemid 351542330)
165. Tsujie M, Uneda S, Tsai H, Seon BK. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 29: 1087-1094, 2006.
166. Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 284: 15794-15804, 2009.
167. van de Kerkhof PC, Rulo HF, van Pelt JP, van Vlijmen-Willems IM, De Jong EM. Expression of endoglin in the transition between psoriatic uninvolved and involved skin. Acta Derm Venereol 78: 19-21, 1998.
168. van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, Driessens MH, Mager JJ, Snijder RJ, Westermann CJ, Doevendans PA, van Echteld CJ, ten Dijke P, Arthur HM, Goumans MJ, Lebrin F, Mummery CL. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 114: 2288-2297, 2006.
169. Velasco S, Alvarez-Muñoz P, Pericacho M, Dijke PT, Bernabéu C, López-Novoa JM, Rodríguez-Barbero A. L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 121: 913-919, 2008. (Pubitemid 351578127)
170. Velasco B, Ramírez JR, Relloso M, Li C, Kumar S, López-Bote JP, Pérez-Barriocanal F, López-Novoa JM, Cowan PJ, d'Apice AJ, Bernabeu C. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther 8: 897-904, 2001. (Pubitemid 32600145)
171. Velasco-Loyden G, Arribas J, López-Casillas F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 279: 7721-7733, 2004. (Pubitemid 38294655)
172. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2: 642-649, 2006. (Pubitemid 43865232)
173. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24: 147-158, 2009.
174. - and endothelium. J Vasc Res 43: 109-119, 2006.
175. Xu P, Wang Y, Piao Y, Bai S, Xiao Z, Jia Y, Luo S, Zhuang L. Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biol Reprod 65: 240-246, 2001. (Pubitemid 32574805)
176. Yallampalli C, Garfield RE. Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol 169: 1316-1320, 1993. (Pubitemid 24001657)
177. Yamashita H, Ichijo H, Grimsby S, Morén A, ten Dijke P, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 1995-2001, 1994.
178. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, Wharton J, Malik AB. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 119: 2009-2018, 2009.
179. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA. Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke 34: 2483-2488, 2003. (Pubitemid 37221969)